Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic
  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Bionoid Pharma Announces Agreement to Acquire AiMaverickIntel.com

TORONTO, ON / ACCESSWIRE / June 18, 2024 / Bionoid Pharma, Inc. ("BINP") (OTC Pink:BINP) today announced that it has entered into a Letter of Intent to acquire AiMaverickIntel.com, a leading Audience Acquisition platform powered by Artificial Intelligence (AI). This strategic acquisition underscores BINP's interest in leveraging advanced technology to enhance audience engagement and acquisition strategies.

This new agreement follows the cancellation of a previously announced agreement to acquire Global Alerts Corp. As detailed in a prior release, Bionoid Pharma signed a binding letter of intent to acquire Global Alerts Corp., however strategic considerations led the company to pursue the acquisition of AiMaverickIntel.com instead.

Wayne Cockburn, CEO of BINP, commented, "We are excited with the opportunity to acquire AiMaverickIntel.com, which marks a significant milestone in our growth strategy. Their platform will empower us to enhance audience targeting and customer acquisition efforts, positioning BINP at the forefront of innovation in the industry."

About AiMaverickIntel.com

AiMaverickIntel.com represents the future of audience engagement. Utilizing state-of-the-art AI technology, the platform revolutionizes how companies identify, reach, and engage their target audience segments. Its advanced algorithms and machine learning capabilities provide actionable insights and optimize customer acquisition processes, resulting in unparalleled efficiency and effectiveness in marketing campaigns. By integrating AiMaverickIntel.com's capabilities, BINP aims to achieve substantial improvements in customer engagement and acquisition metrics, driving sustainable growth and competitive advantage.

The transaction is expected to close in within 45 days, pending customary closing conditions and regulatory approvals.

For further information, contact:

Wayne Cockburn, CEO
Phone: (905) 505-0770

SOURCE: Bionoid Pharma, Inc.



View the original press release on accesswire.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.